We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 03 SEPTEMBER 2012
FTC Sights Set On Pharma Deals – Calls For Additional Hart-Scott-Rodino Reporting

Proskauer Rose LLP
Contributor

Proskauer Rose LLP
Firm Overview Proskauer is an elite global law firm with more than 900 lawyers across key financial...
View firm profileThe Federal Trade Commission has proposed expanding Hart-Scott-Rodino reporting and waiting period obligations for certain pharmaceutical, biologics and medicine manufacturing licenses.
United StatesAntitrust/Competition Law












